Psoriasis - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Psoriasis - Identifying and
Commercializing First-in-Class Innovation
Single User License - 5596 Site User
License - 11192 Corporate User License -
16788 Publication Date - May 2014 Pages -
77 To know more details, email to
debora_at_reportstack.com
2
Summary

• This report  identifies and assesses
  first-in-class innovation in the psoriasis
  development pipeline.
• Over the last decade, a greater understanding of
  the underlying pathophysiology of psoriasis has
  increased emphasis on developing
  immuneomodulating therapies, as opposed to
  largely symptomatic treatments. This is currently
  reflected in a competitive market dominated by
  multiple disease-modifying biologic therapies
  (inhibitors of TNF-a and IL-12/IL-23) and generic
  small-molecule therapies. Despite this, there are
  significant unmet needs in the market, including
  safety concerns regarding immunomodulation. This
  is a particularly important issue for the
  long-term commercial and clinical success of
  psoriatic therapeutics, especially for emerging
  biologics. Another unmet need is ease of drug
  application, as biologic drug delivery is
  invasive and painful.

3
Scope
- A brief introduction to psoriasis,
including symptoms, pathophysiology, and overview
of pharmacotherapy- The changing molecular
target landscape between market and pipeline and
particular focal points of innovation- Overview
of how innovative products are contributing to
the pipeline and market for psoriasis-
Comprehensive review of the pipeline for
first-in-class therapies, analyzed on the basis
of phase distribution, molecule type, molecular
target, and administration route- Identification
and assessment of first-in-class molecular
targets with a particular focus on early-stage
programs of which clinical utility has yet to be
evaluated, as well as literature reviews on novel
molecular targets- Assessment of the licensing
and co-development deals for psoriasis therapies
4
Key Benefits
- Understanding of the focal shifts in molecular
targets in the psoriasis pipeline- Understanding
of the distribution of pipeline programs by phase
of development, molecule type and molecular
target- Scientific and clinical analysis of
first-in-class developmental programs-
Assessment of the valuations of licensed and
co-developed psoriasis treatments- A list of the
first-in-class therapies potentially open to
deal-making opportunities.- Analysis of
financial valuations on licensed or co-developed
first-in-class therapies and generics
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com